- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06295692
En undersøgelse af JNJ-77242113 til behandling af deltagere med generaliseret pustuløs psoriasis eller erytrodermisk psoriasis
En fase 3, multicenter, åben-label undersøgelse til evaluering af effektiviteten og sikkerheden af JNJ-77242113 til behandling af deltagere med generaliseret pustuløs psoriasis eller erytrodermisk psoriasis
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Hokkaido, Japan, 060-0033
- JR Sapporo Hospital
-
Ichinomiya, Japan, 491-8558
- Ichinomiya Municipal Hospital
-
Kitakyushu-shi, Japan, 807-8556
- Hospital of the University of Occupational and Environmental Health
-
Kumamoto, Japan, 860-8556
- Kumamoto University Hospital
-
Nagoya, Japan, 467 8602
- Nagoya City University Hospital
-
Osaka, Japan, 550 0006
- Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
-
Sendai, Japan, 980 8574
- Tohoku University Hospital
-
Shimotsuga Gun, Japan, 321 0293
- Dokkyo Medical University Hospital
-
Shinjuku, Japan, 160 0023
- Tokyo Medical University Hospital
-
Toyoake, Japan, 470-1192
- Fujita Health University Hospital
-
Tsu, Japan, 514 8507
- Mie University Hospital
-
tabashi City, Japan, 173 8606
- Teikyo University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- The study participant has a diagnosis of generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) at screening. For GPP, a diagnosis must be classified based on the criteria for diagnosis of GPP by the Japanese Dermatological Association (JDA); for EP, has a history of plaque-type psoriasis. In addition, has an involved body surface area (BSA) of lesion greater than or equal to (>=) 80 percent (%) at baseline
- Candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous treatment)
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and have a negative urine pregnancy test at Week 0 prior to administration of study intervention
- A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention
- A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study intervention
Exclusion Criteria:
- The study participant has a total score of JDA severity index for GPP >=14 at baseline if participants have a diagnosis of GPP
- The study participant has a differential diagnosis of the erythroderma (for example, erythroderma caused by lymphoma or drug eruption) other than EP
- The study participant has a history of or current diagnosis or signs or symptoms of severe, progressive, or uncontrolled liver, renal; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- The study participant has a history of amyloidosis
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
- The study participant who doesn't meet the criteria of prior/current concomitant therapy and/or history/conditions of infections
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: JNJ-77242113- Participants With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP)
Participants with GPP or EP will receive JNJ-77242113 tablet orally. |
JNJ-77242113 tablet will be administered orally. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Generalized Pustular Psoriasis (GPP) Who Experienced Treatment Success at Week 16
Tidsramme: Week 16
|
Percentage of participants with GPP who experienced treatment success at Week 16 was reported. Treatment success for GPP was defined as at least "minimally improved" rating in Clinical Global Impression (CGI) scale for GPP based on Japanese Dermatological Association (JDA) total score. JDA severity index includes skin symptoms (area of erythema with pustules, total area of erythema, and area of edema; each scored 0-3) and systemic/laboratory findings (fever, white blood cell count, C-reactive protein, and serum albumin; each scored 0-2). JDA total score was sum of 2 assessments ranging from 0 (best) to 17 (worst). CGI ratings were defined as: 1=Very much improved (greater than or equal to [>=]3-point reduction in JDA total score), 2=Much improved (1-2-point reduction), 3=Minimally improved (no change in JDA total score, but >=20 percent (%) reduction in area of erythema with pustules or meaningful improvement in >=1 other parameter), 4=No change, 5=Worsened. Higher score = worsening. |
Week 16
|
|
Percentage of Participants With Erythrodermic Psoriasis (EP) Who Experience Treatment Success at Week 16
Tidsramme: Week 16
|
Percentage of participants with EP who experienced treatment success at Week 16 was reported. Treatment success for EP was defined as at least "minimally improved" rating in CGI scale for EP. The CGI scale is a clinician-rated 5-point scale with the following categories: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Worsened. Higher score indicated worsening. |
Week 16
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentdel af deltagere med GPP, der oplevede behandlingssucces over tid baseret på CGI-skalaen ifølge JDA total score
Tidsramme: Fra baseline (uge 0) til uge 156
|
Fra baseline (uge 0) til uge 156
|
|
Procentdel af deltagere med EP, der oplevede behandlingssucces over tid baseret på CGI-skalaen
Tidsramme: Fra baseline (uge 0) til uge 156
|
Fra baseline (uge 0) til uge 156
|
|
Ændring fra baseline i den samlede score for Japanese Dermatological Association (JDA) Severity Index for GPP over tid
Tidsramme: Fra baseline (uge 0) op til uge 156
|
Fra baseline (uge 0) op til uge 156
|
|
Ændring fra baseline i sværhedsklassificering af JDA-sværhedsindeks for GPP over tid
Tidsramme: Fra baseline (uge 0) op til uge 156
|
Fra baseline (uge 0) op til uge 156
|
|
Ændring fra baseline i legemsoverfladearealet (BSA) af involvering af læsion for EP over tid
Tidsramme: Fra baseline (uge 0) op til uge 156
|
Fra baseline (uge 0) op til uge 156
|
|
Procentdel af deltagere, der opnåede en Investigator's Global Assessment (IGA)-score på Ryddet (0) eller Minimal (1) over tid
Tidsramme: Baseline (uge 0) op til uge 156
|
Baseline (uge 0) op til uge 156
|
|
Procentdel af deltagere, der opnåede en IGA-score på Ryddet (0) over tid
Tidsramme: Baseline (uge 0) op til uge 156
|
Baseline (uge 0) op til uge 156
|
|
Procentuel forbedring fra baseline i Psoriasis Area and Severity Index (PASI) over tid
Tidsramme: Fra baseline (uge 0) op til uge 156
|
Fra baseline (uge 0) op til uge 156
|
|
Ændring fra baseline i Dermatology Life Quality Index (DLQI) score over tid
Tidsramme: Fra baseline (uge 0) op til uge 156
|
Fra baseline (uge 0) op til uge 156
|
|
Procentdel af deltagere, der opnåede DLQI-score på 0 eller 1 over tid
Tidsramme: Baseline (uge 0) op til uge 156
|
Baseline (uge 0) op til uge 156
|
|
Ændring fra baseline i EuroQol-5 Dimension 5-Niveau (EQ-5D-5L) over tid: Domænescores
Tidsramme: Fra baseline (uge 0) op til uge 156
|
Fra baseline (uge 0) op til uge 156
|
|
Ændring fra baseline i EQ-5D-5L over tid: Visual Analog Scale (VAS)-score
Tidsramme: Fra baseline (uge 0) op til uge 156
|
Fra baseline (uge 0) op til uge 156
|
|
Antal deltagere med behandlingsrelaterede bivirkninger (TEAEs) og behandlingsrelaterede alvorlige bivirkninger (TESAEs)
Tidsramme: Baseline (uge 0) op til 160 uger
|
Baseline (uge 0) op til 160 uger
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Janssen Pharmaceutical K.K., Japan Clinical Trial, Janssen Pharmaceutical K.K.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 77242113PSO3005
- 77242113PSO3005 (Anden identifikator: Janssen Research & Development, LLC)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .